login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
STOKE THERAPEUTICS INC (STOK) Stock News
USA
- NASDAQ:STOK -
US86150R1077
-
Common Stock
26.51
USD
+0.44 (+1.69%)
Last: 11/14/2025, 8:00:00 PM
27
USD
+0.49 (+1.85%)
After Hours:
11/14/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
STOK Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
10 days ago - By: Zacks Investment Research
All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
10 days ago - By: Benzinga
6 Analysts Have This To Say About Stoke Therapeutics
10 days ago - By: Zacks Investment Research
- Mentions:
IOVA
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
11 days ago - By: Benzinga
- Mentions:
ACET
RIGL
TEM
AKTX
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
11 days ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
16 days ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
26 days ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
a month ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
a month ago - By: Stoke Therapeutics, Inc.
- Mentions:
BIIB
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
a month ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
a month ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
2 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2 months ago - By: Stoke Therapeutics, Inc.
- Mentions:
BIIB
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
2 months ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
3 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025
3 months ago - By: Stoke Therapeutics, Inc.
- Mentions:
BIIB
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
3 months ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
3 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
3 months ago - By: Zacks Investment Research
- Mentions:
MRSN
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
3 months ago - By: Stoke Therapeutics, Inc.
- Mentions:
BIIB
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
3 months ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
3 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
3 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
3 months ago - By: Zacks Investment Research
- Mentions:
MRUS
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
4 months ago - By: Stoke Therapeutics, Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Stoke Therapeutics, Inc.
- Mentions:
BIIB
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
4 months ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Please enable JavaScript to continue using this application.